HC Wainwright Issues Pessimistic Estimate for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Dianthus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($3.06) per share for the year, down from their prior forecast of ($2.33). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

Several other equities analysts also recently weighed in on DNTH. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Raymond James increased their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Oppenheimer lifted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wedbush lowered their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $25.49 on Thursday. The firm has a market cap of $754.43 million, a P/E ratio of -10.20 and a beta of 1.84. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The business has a 50-day moving average of $27.65 and a 200 day moving average of $26.63.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Quest Partners LLC lifted its position in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics in the second quarter worth $236,000. Fred Alger Management LLC increased its stake in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after acquiring an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the second quarter valued at about $265,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.